Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 6, Issue 2, 2010, Pages 382-390

  Alizadeh, Darya ^a   Zhang, Leying ^a   Hwang, Jungyeon ^b   Schluep, Thomas ^b   Badie, Behnam ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Calando Pharmaceuticals   (United States)

Author keywords

Brain neoplasm; Central nervous system; Microglia; Nanoparticle

Indexed keywords

BRAIN NEOPLASMS; BRAIN TUMORS; CELLULAR DISTRIBUTIONS; CENTRAL NERVOUS SYSTEMS; DRUG CARRIER; FLOW CYTOMETRY ANALYSIS; FLUORESCENT MICROSCOPY; GLIOMA CELLS; IN-VITRO; INTRACRANIAL TUMORS; MICROGLIA; TUMOR SITE;

BRIDGE BEARINGS; CELL CULTURE; FLOW CYTOMETRY; MACROPHAGES; NANOPARTICLES;

TUMORS;

CYCLODEXTRIN; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CELL MIGRATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG UPTAKE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GLIOMA; GLIOMA CELL; IN VITRO STUDY; MICROGLIA; MOUSE; NONHUMAN; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CYCLODEXTRINS; DRUG CARRIERS; GLIOMA; MACROPHAGES; MICE; NANOPARTICLES;

MURINAE; MUS;

EID: 77950044670     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2009.10.001     Document Type: Article

References (42)

1. Muldoon L.L., Soussain C., Jahnke K., Johanson C., Siegal T., Smith Q.R., et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25 (2007) 2295-2305
2. Pardridge W.M. Drug targeting to the brain. Pharm Res 24 (2007) 1733-1744
3. Patel M.M., Goyal B.R., Bhadada S.V., Bhatt J.S., and Amin A.F. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 23 (2009) 35-58
4. Jain K.K. Use of nanoparticles for drug delivery in glioblastoma multiforme. Expert Rev Neurother 7 (2007) 363-372
5. Byrne J.D., Betancourt T., and Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60 (2008) 1615-1626
6. Reimold I., Domke D., Bender J., Seyfried C.A., Radunz H.E., and Fricker G. Delivery of nanoparticles to the brain detected by fluorescence microscopy. Eur J Pharm Biopharm 70 (2008) 627-632
7. Galea I., Bechmann I., and Perry V.H. What is immune privilege (not)?. Trends Immunol 28 (2007) 12-18
8. Djukic M. Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice. Brain 129 (2006) 2394-2403
9. Badie B., and Schartner J.M. Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 46 (2000) 957-961 discussion 61-2
10. Roggendorf W., Strupp S., and Paulus W. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol 92 (1996) 288-293
11. Shinonaga M., Chang C.C., Suzuki N., Sato M., and Kuwabara T. Immunohistological evaluation of macrophage infiltrates in brain tumors. Correlation with peritumoral edema. J Neurosurg 68 (1988) 259-265
12. Streit W.J. Cellular immune response in brain tumors. Neuropathol Appl Neurobiol 20 (1994) 205-206
13. Hussain S.F., Yang D., Suki D., Grimm E., and Heimberger A. Innate immune functions of microglia isolated from human glioma patients. J Transl Med 4 (2006) 15
14. Nickles D., Abschuetz A., Zimmer H., Kees T., Geibig R., Spiess E., et al. End-stage dying glioma cells are engulfed by mouse microglia with a strain-dependent efficacy. J Neuroimmunol 197 (2008) 10-20
15. Schluep T., Cheng J., Khin K.T., and Davis M.E. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol 57 (2006) 654-662
16. VanHandel M., Alizadeh D., Zhang L., Kateb B., Bronikowski M., Manohara H., et al. Selective uptake of multi-walled carbon nanotubes by tumor macrophages in a murine glioma model. J Neuroimmunol 208 (2009) 3-9
17. Schluep T., Gunawan P., Ma L., Jensen G.S., J.D., S.H., et al. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin Cancer Res 15 1 (2009) 181-189
18. Badie B., Bartley B., and Schartner J. Differential expression of MHC class II and B7 costimulatory molecules by microglia in rodent gliomas. J Neuroimmunol 133 (2002) 39-45
19. Brannon-Peppas L., and Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56 (2004) 1649-1659
20. Schluep T., Hwang J., Cheng J., Heidel J.D., Bartlett D.W., Hollister B., et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 12 (2006) 1606-1614
21. Watters J.J., Schartner J.M., and Badie B. Microglia function in brain tumors. J Neurosci Res 81 (2005) 447-455
22. Galarneau H., Villeneuve J., Gowing G., Julien J.P., and Vallieres L. Increased glioma growth in mice depleted of macrophages. Cancer Res 67 (2007) 8874-8881
23. Schartner J.M., Hagar A.R., Van Handel M., Zhang L., Nadkarni N., and Badie B. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 51 4 (2005) 279-285
24. Sica A., and Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117 (2007) 1155-1166
25. Condeelis J., and Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124 (2006) 263-266
26. Lewis C.E., and Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res 66 (2006) 605-612
27. Pardoll D. Does the immune system see tumors as foreign or self?. Annu Rev Immunol 21 (2003) 807-839
28. Sica A., Schioppa T., Mantovani A., and Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42 (2006) 717-727
29. Komohara Y., Ohnishi K., Kuratsu J., and Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 216 (2008) 15-24
30. Murat A., Migliavacca E., Gorlia T., Lambiv W.L., Shay T., Hamou M.F., et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26 (2008) 3015-3024
31. Nishie A., Ono M., Shono T., Fukushi J., Otsubo M., Onoue H., et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res 5 (1999) 1107-1113
32. Wesolowska A., Kwiatkowska A., Slomnicki L., Dembinski M., Master A., Sliwa M., et al. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion-an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene 27 (2008) 918-930
33. Zimmer C., Weissleder R., Poss K., Bogdanova A., Wright Jr. S.C., and Enochs W.S. MR imaging of phagocytosis in experimental gliomas. Radiology 197 (1995) 533-538
34. Jackson H., Muhammad O., Daneshvar H., Nelms J., Popescu A., Vogelbaum M.A., et al. Quantum dots are phagocytized by macrophages and colocalize with experimental gliomas. Neurosurgery 60 (2007) 524-529 discussion 9-30
35. Trehin R., Figueiredo J.L., Pittet M.J., Weissleder R., Josephson L., and Mahmood U. Fluorescent nanoparticle uptake for brain tumor visualization. Neoplasia 8 (2006) 302-311
36. Carpentier A.F., Tibi A., Richard M., Capelle L., Laigle-Donadey F., Behin A., et al. Local treatment with an immunostimulatory CpG-oligonucleotide in patients with recurrent glioblastoma: results of a phase I trial. Presented at: Second Quadrennial Meeting of the World Federation of Neuro-Oncology (May 5-8 2005) Edinburgh, UK
37. Hussain S.F., Kong L.Y., Jordan J., Conrad C., Madden T., Fokt I., et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67 (2007) 9630-9636
38. Kortylewski M., and Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 20 (2008) 228-233
39. Yen Y., Synold T., Schluep T., Hwang J., Oliver M., and Davis M.E. First-in-human phase I trial of a cyclodextrin-containing polymer-camptothecin nanoparticle in patients with solid tumors. J Clin Oncol 25 18S (2007) 14078
40. Briegert M., and Kaina B. Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents. Cancer Res 67 (2007) 26-31
41. Davoust N., Vuaillat C., Androdias G., and Nataf S. From bone marrow to microglia: barriers and avenues. Trends Immunol 29 (2008) 227-234
42. Valable S., Barbier E.L., Bernaudin M., Roussel S., Segebarth C., Petit E., et al. In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma. NeuroImage 40 (2008) 973-983